The healthcare industry, a sector defined by its mission to save lives, is increasingly grappling with a profound contradiction: its own operational footprint is damaging the very environment upon which human health depends. While global pharmaceutical and biotechnology giants have rolled out ambitious, high-profile sustainability pledges, the industry’s actual carbon output continues to climb. This growing disparity between public commitments and empirical reality highlights the immense challenges of decarbonizing one of the world’s most resource-intensive manufacturing sectors.
The Magnitude of the Impact: Main Facts
The healthcare sector is a significant contributor to the global climate crisis, responsible for approximately 4.4% of total global greenhouse gas (GHG) emissions annually. Within this footprint, the pharmaceutical and biotechnology supply chain is a primary driver, accounting for roughly 71% of the sector’s total emissions.
At the heart of the problem is the carbon-heavy nature of drug development. Medicines themselves contribute between 20% and 55% of healthcare’s total carbon footprint, driven by intensive corporate operations, Active Pharmaceutical Ingredient (API) production, and complex global manufacturing processes. Pharmaceutical manufacturing is notoriously inefficient; for every one kilogram of an active drug produced, the industry typically generates between 25 and 100 kilograms of chemical waste. Furthermore, solvents—the primary component of Process Mass Intensity (PMI)—often account for 80% to 90% of total mass in pharmaceutical workflows. With a median PMI ranging from 168 to 308, the pharmaceutical sector is significantly more resource-intensive than many other chemical industries.
Beyond carbon, the industry faces an ecological crisis regarding chemical runoff. Pharmaceutical residues enter the environment through patient excretion, industrial plant emissions, and the improper disposal of unused medicines. While current concentrations in drinking water are generally categorized as low-risk for immediate human toxicity, the long-term ecological consequences remain a major concern. Of particular urgency is the role of manufacturing effluents in promoting antibiotic resistance; the release of antibiotic residues into waterways can foster the development of "superbugs," creating a potential public health catastrophe that mirrors the climate crisis in its complexity.
A Chronology of the Emissions Trend
The trajectory of the industry’s carbon footprint over the last five years tells a story of mounting pressure and limited progress.
- 2020–2021: The total carbon output of public pharmaceutical companies surged by 15%, rising from 197 million tCO2e to 227 million tCO2e.
- 2022: The sector’s contribution to global emissions rose to 5%, up from 3.9% the previous year, signaling an accelerating trend rather than a plateau.
- 2023–2024: Despite the widespread adoption of net-zero targets, the industry saw an absolute increase in emissions of 2%.
- 2025: A pivot point for transparency. The My Green Lab 2025 Carbon Impact Report noted that while sector alignment with 1.5°C climate trajectories improved—rising from 30% in 2024 to 52% in 2025—the total volume of emissions remained high, driven largely by massive corporate acquisitions and expanded production capacity.
Supporting Data: The Scope 3 Conundrum
To understand why emissions are rising despite sustainability efforts, one must look at the GHG Protocol’s categorization. Companies have largely succeeded in trimming Scope 1 (direct emissions from owned sources) and Scope 2 (indirect emissions from purchased energy). However, Scope 3 emissions—those occurring throughout the value chain, including purchased goods, logistics, and product disposal—represent a staggering 82% of the industry’s total footprint.
Scope 3 emissions are notoriously difficult to control because they occur outside a company’s direct infrastructure. They include the synthesis of APIs by third-party contractors, the carbon cost of raw material extraction, the construction of massive capital assets, and global shipping.
Data from industry leaders illustrates this struggle:
- AstraZeneca: While successfully reducing operational emissions, the company saw its absolute Scope 3 emissions climb by 24% compared to its 2019 baseline.
- Eli Lilly: The company’s Scope 3 footprint rose sharply from approximately 2.99 million metric tons in 2021 to 5.14 million in 2023.
- Novo Nordisk: In a stark example of how scaling production impacts climate goals, the company reported a 19% increase in total emissions between 2024 and 2025, largely attributed to the acquisition of new, energy-intensive production sites to meet global demand for high-growth therapeutics.
Official Corporate Responses and Initiatives
In response to public and regulatory scrutiny, major players have staked their reputations on ambitious climate goals.
AstraZeneca has positioned itself as an industry leader, reporting that it is currently on track to achieve a 98% reduction in operational emissions by 2026. Their 2025 progress report highlighted a 23% reduction in water usage and a 13% reduction in waste, demonstrating that operational efficiency is achievable when prioritized.
Sanofi has adopted a similarly aggressive stance, aiming for total carbon neutrality by 2030. As of 2024, the company reported a 47% reduction in emissions compared to its 2019 baseline. Furthermore, Sanofi has pledged that 100% of its manufacturing sites will implement rigorous monitoring and management plans to mitigate the release of pharmaceuticals into the environment, directly addressing concerns regarding biodiversity and water safety.
However, these companies acknowledge that individual efforts are often neutralized by the broader industry’s reliance on carbon-intensive, outsourced manufacturing hubs, where regulatory oversight and energy-transition capabilities vary wildly by region.
The Implications: Why Progress Stalls
The failure to meaningfully decouple production growth from emissions growth carries severe implications for both the industry and the planet.
The Scale-up vs. Sustainability Conflict
The primary driver of rising emissions is the rapid scale-up of production required to meet the demands of an aging global population and the rise of complex, biologic-based therapies. When a company acquires new sites or shifts to new chemical manufacturing processes to meet market demand, the immediate impact is often an increase in energy use that dwarfs the marginal gains made by energy-efficiency retrofits in older facilities.
The Limits of Voluntary Action
The current reliance on voluntary sustainability goals has led to a fragmented landscape. While the top 25 public companies have made notable strides, they are often overshadowed by smaller, private firms that lack the reporting infrastructure or the capital to invest in green chemistry. Furthermore, because Scope 3 emissions are the "hidden" cost of doing business, the lack of standardized, global supply-chain reporting allows for significant gaps in accountability.
Strategic Shifts Needed
To turn the tide, the industry must move beyond mere target-setting. The path forward requires a fundamental shift in three areas:
- Supply Chain Integration: Pharma companies must move from "requesting" sustainability from suppliers to mandating it through strict contractual obligations and by helping suppliers transition to renewable energy sources.
- Logistical Overhaul: Reducing reliance on carbon-heavy air freight in favor of sea and road logistics is essential for reducing Scope 3 logistics emissions.
- Green Chemistry Innovation: The industry must invest in R&D to reduce Process Mass Intensity. By redesigning chemical pathways to use fewer solvents and catalysts, the industry can reduce its waste and energy usage at the molecular level, before the production cycle even begins.
Conclusion
The pharmaceutical industry is currently caught in a transition phase. While the technological and operational frameworks for a sustainable future exist, they are currently outpaced by the sheer volume of global demand. The disconnect between the 52% of companies aligned with 1.5°C trajectories and the continued rise in absolute emissions serves as a sobering reminder that policy, innovation, and supply-chain management must move in lockstep.
As the world continues to rely on the pharmaceutical sector to address health crises, the industry must prove that it can fulfill its fundamental mandate—the preservation of life—without compromising the stability of the global environment. The coming decade will be the ultimate test of whether the pharmaceutical sector can pivot from being a major contributor to the climate crisis into an essential partner in solving it.
About the Author
